By acting in the central nervous system, circulating insulin may regulate food intake and body weight. We have previously shown that the kinetics of insulin uptake from plasma into cerebrospinal fluid (CSF) can best be explained by passage through an intermediate compartment. To determine if transport kinetics into this compartment were consistent with an insulin receptor-mediated transport process, we subjected overnight fasted, anesthetized dogs to euglycemic intravenous insulin infusions for 90 min over a wide range of plasma insulin levels (69-5,064 ,U/ml) (n = 10). Plasma and CSF samples were collected over 8 h for determination of immunoreactive insulin levels, and the kinetics of insulin uptake from plasma into CSF were analyzed using a compartmental model with three components (plasma --intermediate compartment -CSF). By sampling frequently during rapid changes of plasma and CSF insulin levels, we were able to precisely estimate three parameters (average standard deviation 14%) characterizing the uptake of insulin from plasma, through the intermediate compartment and into CSF (klk2); insulin entry into CSF and insulin clearance from the intermediate compartment (k2 + k3); and insulin clearance from CSF (k4). At physiologic plasma insulin levels (80±7.4,gU/ml), klk2 was determined to be 10.7 X 10'±+1.3 X 10-6 min2. With increasing plasma levels, however, k1k2 decreased progressively, being reduced sevenfold at supraphysiologic levels (5,064 ,U/ml). The apparent KM of this saturation curve was 742 uUU/ml ( -5 nM). In contrast, the rate constants for insulin removal from the intermediate compartment and from CSF did not vary with plasma insulin (k2 + k3 = 0.011±0.0019 min' and k4 = 0.046±0.021 min').
Introduction
Several lines of investigation suggest that circulating insulin levels within the physiologic range exert biologic effects on functioning of the central nervous system (CNS). For exam-ple, experimental elevations of plasma insulin to postprandial values suppress feeding behavior (1, 2) , an effect also observed during direct insulin infusion into the brain (3) . That this occurs despite the extensive network of endothelial tight junctions in cerebral vasculature comprising the blood-brain barrier, which limits diffusion of peptides of this size, suggests that circulating insulin may enter the brain via a facilitated transport process (4) . In vitro studies (5, 6) demonstrating that insulin transport across vascular endothelium is dependent on its binding to endothelial insulin receptors have led to the hypothesis that receptor-mediated insulin transport may facilitate the delivery ofcirculating insulin to target tissues in vivo. Moreover, brain microvascular endothelium expresses insulin receptors (7) , and the uptake of plasma insulin into cerebrospinal fluid (CSF)' demonstrates specificity when compared to analogues with reduced affinity for the insulin receptor, such as proinsulin (8) . These and other studies (9) provide support for the hypothesis that the entry of circulating insulin into the brain is facilitated by an insulin receptor-mediated transport process. However, quantitative measurements ofinsulin transport kinetics into the CNS have yet to address the possibility of saturable insulin transport.
In our previous work ( I0), we provided evidence that insulin uptake from plasma into CSF requires passage through an intermediate compartment, and reported on the use of a compartmental model to facilitate the analysis of this uptake process. We now report the quantitation of the dose-response relationship between the plasma insulin level and kinetics of insulin uptake from plasma, through an intermediate compartment, and into CSF. We hypothesized that if insulin receptors, localized to either the blood-brain or blood-CSF barrier, facilitate this uptake process, then the rate constant characterizing CSF insulin uptake should be saturable, decreasing in magnitude with increasing plasma insulin levels. Moreover, the plasma insulin concentration at which half-maximal transport occurs (KM) should be comparable to the dissociation constant (KD) of the insulin receptor.
Methods
Study animals and conditions. Six normal adult male mongrel dogs weighing 20-30 kg were studied after an overnight fast. Mills, Inc., Memphis, TN) with unlimited access to water. For each study, each dog was anesthetized with thiamylol (Surital, Parke-Davis, Morris Plains, NJ), 20 mg/kg i.v., and was placed on mechanical ventilation, with 1-2% halothane and 40% 02-Intravenous catheters were placed for both sampling and infusion, and the cisternum magnum was cannulated with a no. 22 gauge spinal needle for sampling of CSF, as reported previously (10) . Body weight was measured immediately before each study. All studies were approved by the Animal Care Committee of the Seattle VA Medical Center.
Insulin infusion and sampling. The study protocol consisted of a 90-mm i.v. insulin infusion period with sampling of plasma and CSF for a total of490 min. Intravenous insulin was administered as a 3-min primed infusion (8.5-50 mU/kg-min) commencing at t = 0 min, followed by a continuous infusion for 87 min at 20% of the primed infusion rate. Blood samples ( 1.8 ml) were obtained at t = -10, -5, 1,2, 3, 4, 6, 8, 10, 13, 16, 20, 25, 30, 35, 40, 65 , and 90 min, at 5-min intervals for 90 < t < 150 min, and at 20-min intervals for 150 < t < 490 min. CSF samples (0.4 ml) were obtained at t = -10, -5, 20, 40, 65, 90, 95, 100, 110, 120, 135, and 150 min and thereafter at 20-min intervals until 490 min. In three studies (P81, P520, and P1195), additional blood and CSF samples were taken at 20-min intervals for 510 < t < 590 min. Euglycemia was maintained in all studies by a variable-rate i.v. infusion of 50% dextrose with on-line monitoring of blood glucose levels using a hand-held, computerized glucose meter (Glucoscan, Lifescan, American Medical Systems, Cincinnati, OH). Blood and CSF samples were placed on ice before processing. After blood separation, both plasma and CSF were frozen at -20'C until assay. Plasma levels of immunoreactive insulin (IRI) were measured in duplicate by radioimmunoassay using a modification of the double-antibody method (11) . CSF IRI was measured in triplicate using a further modification of this method which enhances its sensitivity (8, 12) . Plasma glucose was determined by the glucose oxidase method with a glucose autoanalyzer (Beckman Instruments, Inc., Brea, CA). The average plasma insulin concentration during infusion, Pave, was determined by taking the average of plasma insulin values during the interval 1 . t < 90 min. Two dogs were studied once at either a low or high insulin dose, and four were studied twice, at both a low and high insulin dose. Thus, 10 independent data sets were obtained.
Multicompartmental model. A schematic illustration of the multicompartment model used to interpret the data is shown in Fig. 1 ; this model was previously described in Schwartz et al. (10) . Because ofthe delay in the appearance ofinsulin in the CSF after intravenous insulin infusion, insulin entry from plasma into CSF can best be explained by passage through an 
dt dINSc(t) = k2INSI(t) -k4INSc(t) (2) INSp ( plasma and CSF levels were subtracted from all values of each data set before modeling, such that for modeling purposes the insulin concentration in each compartment was set equal to zero at t = 0 min. Therefore, only the kinetics of infused insulin were analyzed, and it was not necessary to assume that at the basal state all CSF IRI must be derived from plasma. Because the intermediate compartment was not directly sampled, only the rate constant characterizing insulin clearance from CSF, k4, can be identified independently, whereas ki, k2, and k3 are not independently identifiable. Instead, the product klk2, which represents the throughput of insulin from plasma, through the intermediate compartment, and subsequently into CSF, and sum (k2 + k3), which represents insulin flux from the intermediate compartment into CSF as well as insulin clearance from the intermediate compartment, were estimated. A detailed derivation of unique parameter identification is provided in the Appendix.
Parameter identification. By using the mathematical modeling program SAAM ( 13) on a model 486 computer (Gateway 2000, Gateway, Sioux City, SD), the rate constants kk2 (min2), (k2 + k3) (min-'), and k4 (min -') were estimated from the plasma and CSF insulin data.
To reduce the number of samples and therefore total fluid volumes required per study, only CSF insulin data points taken during t 2 90 min were used for modeling. It can be shown that as long as enough plasma and CSF samples are taken and steady state is reached, the same parameters will be obtained from CSF samples taken at 0 < t < 3, 3 < t < 90, or t . 90 min ( 14). The intraassay errors for the plasma and CSF insulin radioimmunoassays were assessed by measuring eight samples of various insulin concentrations (data not shown). These error estimates (plasma insulin assay 4% for concentrations < 80 AU/ml, 12% otherwise; CSF insulin assay 1 1%) were used by SAAM to determine the optimal curve fit and to identify the rate constant parameters. For each parameter, the corresponding coefficient of variation (CV), also known as the fractional standard deviation, was determined from the covariance matrix generated by SAAM.
Independent estimation ofthe CSF insulin clearance parameter, ki4.
To obtain an independent estimate of k4, the CSF insulin clearance parameter, insulin (750 /U in 750 AI of saline) was infused over 1 min into the cistemum magnum of three dogs which had been fasted overnight, anesthetized, and maintained on mechanical ventilation. Immediately before the infusion was administered, 750 Ml of CSF was removed from the cisternum magnum, in order to preserve the original volume of CSF during the infusion. CSF samples (0.4 ml) were obtained at t = -10, -5, 2, 5, 10, 15, 25, and 40 min, and thereafter at 20-min intervals till 240 min. The resulting CSF levels decayed biexponentially, and were fitted to a two-compartment model. This twocompartment analysis has previously been used to model transport kinetics ofsubstances administered intracerebroventricularly, with one compartment representing CSF and the other representing brain interstitium ( 15, 16) . The CSF clearance rate was calculated by dividing the estimated bolus concentration administered by the area under the curve of the two exponentials ( 17 ) .
Estimation ofKM, the plasma insulin concentration at which halfmaximal transport occurs. To estimate KM, the plasma insulin concentration at which half-maximal transport occurs, the transport velocity for various plasma insulin concentrations was required. Velocity is determined by multiplying ki, the rate constant representing uptake of plasma insulin into the intermediate compartment, by the corresponding plasma insulin concentration during infusion, Pave. As kI could not be uniquely identified, the product klk2, which estimated ki, was used for this calculation. Therefore, velocity*k2, which is directly proportional to the rate of insulin uptake from plasma into CSF, was instead calculated. Velocity * k2 due to nonspecific uptake is linear, such that at high plasma insulin levels, velocity * k2 does not plateau. As 
Results
The 90-min intravenous insulin infusion protocol resulted in a characteristic time course of change in CSF IRI levels, illustrated in Fig. 2 . During i.v. insulin infusion, CSF insulin levels rose gradually, reaching peak values at 105 min ( 15 min after discontinuation of infusion), and fell exponentially thereafter. The estimated parameters and corresponding coefficients of variation for each study are given in Table I . The mean CV for all estimated parameters was 14%.
The data in Table I To further characterize these relationships, klk2, (k2 + k3), and k4 were plotted as a function ofthe average plasma insulin concentration during infusion, Pave, to determine dose-response relationships. As shown in Fig. 3 , the parameter characterizing insulin uptake from plasma into CSF varied inversely with plasma insulin levels, being reduced sevenfold from physiologic to supraphysiologic levels. The apparent KM for this transport process was determined from a Michaelis-Menten dose-response curve based on the data in Table I . As shown in Fig. 4 , the apparent KM was approximated to be 742 ,uU/ml ( -5 nM). In contrast, the mean rate constant values for insulin removal from the intermediate compartment (k2 + k3) and insulin clearance from CSF (k4) did not appear to vary with plasma insulin (k2 + k3 = 0.011±0.0019 min-' and k4 = 0.046±0.021 min-') ( Fig. 5) 
In studies P81 and P1194, plasma insulin samples were not taken at t = 1, 2, 3, 4, 6, 8, 10, 13, and 16 min, which resulted in higher coefficients of variation than in studies in which these samples were obtained. Studies conducted in the same dog were P69 and P989, P81 and P1203, P520 and P1194, and P86 and P5064.
also determined independently by modeling data from intracisternal insulin injection (n = 3). The intracisternal insulin injection protocol resulted in a characteristic time course of change in CSF IRI levels, illustrated in Fig. 6 . The mean CSF insulin clearance rate determined from these studies was 0.028 ± 0.0080 min-', which is within the error ofthe mean value of k4 determined during i.v. insulin infusion (Fig. 7) . These results validate the CSF insulin clearance parameter identified during intravenous insulin infusion.
Discussion
In the current studies, we analyzed the kinetics of CSF insulin uptake from plasma using a previously presented multicompartmental model (10). Our results indicate that the efficiency with which circulating insulin enters CSF via passage through an intermediate compartment varies inversely with the plasma insulin concentration. These data support the hypothesis that insulin entry into the CNS from plasma is facilitated by a saturable transport process. As the efficiency of uptake into the CNS decreases sevenfold with increasing plasma insulin concentration, we estimate that 85% ofthis uptake is mediated by a saturable process at physiologic plasma insulin levels (< 100
,uU/ml). The apparent KM of this transport process was 742 /gU/ml (-5 nM), which is similar to the KD of the insulin receptor identified in brain microvasculature (2 nM) (19). Therefore, data are consistent with the hypothesis that insulin receptors facilitate transport of plasma insulin into the central nervous system. the choroid plexus. One hypothesis to account for this observation is that insulin entering the choroid plexus is sequestered by choroidal insulin receptors, which are expressed at high concentrations, preventing its diffusion into CSF, and are possibly 6(X) responsible for degrading insulin following binding, as occurs in the placenta (20, 21 Two barrier systems exist in the central nervous system which regulate solute movement between the blood and CNS. The first of these is the blood-brain barrier, which arises from epithelial-like tight junctions that virtually cement adjoining capillary endothelium together in the brain microvasculature. Similarly, the blood-CSF barrier arises from tight junctions between adjacent epithelial cells investing the choroid plexus, the primary site of CSF formation. In general, most solutes gain access from blood to CSF via the blood-CSF barrier at the choroid plexus. Transport of solutes such as Na' occurs directly from blood to CSF, and does not necessitate postulating transport through an intermediate compartment ( 16 40% of plasma levels (22) , whereas CSF levels are < 5% of plasma levels, for example, suggests that insulin uptake occurs preferentially across the blood-brain barrier, rather than the blood-CSF barrier. Moreover, blood-brain barrier endothelium expresses insulin receptors (4, 23) , and after intracarotid injection of radiolabeled insulin, penetration of insulin tracer into brain parenchyma was inhibited by coadministration of excess insulin in newborn rabbits (9) , suggesting a saturable transport process within the blood-brain barrier. Taken together, these data support the hypothesis that a saturable transport system operates at the level of the blood-brain barrier to promote the delivery of circulating insulin to target sites in the brain. Analogous blood-brain barrier transport systems have been described for glucose (24) , amino acids (25) , plasma proteins such as transferrin (26) , and peptides such as enkephalins (27) (28) or cisterna magna in dogs (8, 10) , suggesting that the choroid is unlikely to represent the major source of insulin in CSF. Further, the teleologic rationale for a specialized transport system for insulin across the choroid into CSF is unclear, since this uptake results in relatively low CSF insulin levels, and recent studies have established that infusion of insulin into CSF is an inefficient means for its delivery into the brain. For example, 100-1,000-fold greater CSF infusion rates are required to achieve effects on food intake comparable to those resulting from direct intrahypothalamic insulin delivery (29 pression offood intake), regulation ofneuropeptide biosynthesis and catecholamine metabolism, and activation of the sympathetic nervous system. Collectively, these central actions promote a state of negative energy balance, favoring weight loss. These observations have led to the hypothesis that circulating insulin acts in the brain as a negative feedback signal proportional to body adipose mass in the process of long-term body weight regulation (30, 31 ) . From the available data, we believe that plasma insulin is delivered to brain interstitial fluid at least in part via an insulin receptor-mediated transcytotic process. As most insulin-receptor mediated actions are subject to a variety ofregulatory influences, it is possible that this insulin transport process may also be regulated, which would be unlikely were transport dependent solely on nonsaturable mechanisms such as diffusion. Theoretically, regulation of CNS insulin transport could alter the efficiency with which circulating insulin gains access to target sites in the brain, and could thus represent an important determinant of the level about which body weight is maintained.
Receptor-mediated insulin transport from vasculature to tissue interstitium may regulate processes other than body weight. The movement of insulin from blood into the interstitium oftissues is an important determinant ofthe rate of insulin action on carbohydrate utilization in vivo. Yang et al. (32) have shown a strong correlation between the dynamics of thoracic duct lymph insulin, which is derived from interstitial fluid, and insulin mediated glucose utilization. Further, lymph insulin is proportional to glucose utilization within the physiologic but not pharmacologic range of insulin, indicating that transcapillary insulin transport is rate-limiting for insulin action in this range (33) . Thus, the movement of insulin from vasculature to interstitium is a critical step in determining tissue sensitivity to insulin, and it is possible that defects in transport may contribute to the pathogenesis ofinsulin resistance in conditions such as non-insulin-dependent diabetes mellitus and obesity. It should be stressed, however, that while we have demonstrated saturable uptake of insulin into CSF, studies have yet to establish a saturable mechanism of insulin transport into peripheral interstitial fluid. It is possible that mechanisms operating within brain vasculature differ from those of other tissues where insulin uptake is concerned.
It should be noted that the estimated k1k2 values in the supraphysiologic range of plasma insulin levels in the current studies are about half those calculated previously (10). These differences are probably attributable to modified plasma and CSF sampling schedules, which have improved parameter estimates. Specifically, the number of samples taken during rapid changes of plasma and CSF insulin levels was increased. This change of sampling times reduced the variability of estimated parameters, compared to those generated using conventional sampling procedures (34) . In our previous work, estimated parameters often had associated coefficients of variation > 100%. In contrast, the mean coefficient of variation for 30 identified parameters in the current studies is 14%. In both cases, the true parameter value was located within the coefficient ofvariation ofeach estimate. However, because the coefficients ofvariation have been reduced in the current studies, the mean estimates are now much closer to the true parameters than in the previous work.
In the current studies, we measured k4, the rate of insulin clearance from CSF, to be 0.046±0.021 min-'. This clearance rate was independently verified by intracerebroventricular administration of insulin, and is much higher than the rate of bulk flow CSF clearance in the dog (0.0025±0.0003 min '), as determined from previous inulin studies (10, 15, 16) . This large disparity between CSF clearance rates suggests that mechanisms other than bulk flow contribute to insulin removal from CSF. One possibility is that insulin receptors on the choroid plexus bind and remove/degrade insulin in CSF, as suggested by Manin et al. (35) . While this would imply a saturable mechanism for CSF insulin removal, saturability would not be demonstrable at such low CSF insulin levels as occurred in our studies (< 10 ,U/ml). Thus, while CSF insulin removal may involve a saturable mechanism, further study is required to address this possibility.
In summary, we have demonstrated that uptake of plasma insulin into the central nervous system is saturable. This mechanism is consistent with insulin binding to blood-brain barrier and/or blood-CSF insulin receptors and subsequent transcytosis into the central nervous system.
